Why this trending supplement belongs in every medication history conversation
Your patient is taking a supplement that may be quietly cutting the effectiveness of the pain medication you’re about to prescribe. It isn’t on their medication list, because they don’t think of it as a medication.
It’s berberine — and right now it’s one of the most searched-for products in the wellness aisle.
If you spend any time on social media, you’ve seen it crowned “Nature’s Ozempic,” a plant-based shortcut to weight loss and steadier blood sugar. The comparison is catchy. It’s also, as usual, telling a very different story than the pharmacology does.
What berberine actually is
Berberine isn’t new and it isn’t fringe. It’s a bright-yellow alkaloid found in goldenseal, barberry, and Oregon grape, used in traditional medicine for centuries. Modern research has focused on its effects on blood sugar and lipids, and there is legitimate signal there — berberine does appear to modestly improve glucose regulation and some cardiometabolic markers.
The problem is the “Ozempic” part. Semaglutide and the other GLP-1 agonists have been studied in large, long-term trials showing meaningful weight loss and reduced cardiovascular events. Berberine hasn’t. The National Center for Complementary and Integrative Health notes that human weight-loss data are limited, inconsistent, and largely drawn from studies with a high risk of bias. “Nature’s Ozempic” isn’t a scientific claim. It’s a marketing one.
The part that matters chairside
Here’s why this belongs in your operatory, and it has almost nothing to do with weight loss.
Berberine is a potent inhibitor of the cytochrome P450 enzyme system — the machinery responsible for processing a large share of the medications your patients take. In a controlled human study, two weeks of berberine reduced the activity of CYP2D6, CYP2C9, and CYP3A4. When those enzymes slow down, drug levels in the bloodstream climb, sometimes into the range where side effects or toxicity become a real concern.
One finding in that study should stop you cold: two weeks of berberine reduced CYP2D6 activity roughly ninefold.
That enzyme matters more than its name suggests. Codeine is itself inactive — it relies on CYP2D6 to convert into morphine, the form that actually relieves pain. Blunt that enzyme and your patient converts far less codeine into its active form, and gets little relief from a standard dose. Tramadol depends on the same pathway.
So a patient who quietly added a berberine capsule to their morning routine could find their post-operative pain medication underperforming, and nothing on their medication list would explain why.
And it doesn’t stop there
Because berberine lowers blood glucose on its own, it can compound the effects of metformin, sulfonylureas, and insulin — raising the possibility of hypoglycemia. It’s also been shown to raise blood levels of cyclosporine in transplant patients.
These aren’t exotic scenarios. These are medications your patients take every day.
The wrinkle that makes this harder
Berberine does have genuine antimicrobial activity. Laboratory studies show it active against Streptococcus mutans, Porphyromonas gingivalis, and Aggregatibacter actinomycetemcomitans, and small studies of berberine-containing rinses and gels have reported reductions in plaque and gingival inflammation.
That sounds like good news, and in isolation it is. But it also reinforces a patient’s belief that berberine is wholesome, harmless, and beneficial across the board. The antimicrobial story and the drug-interaction story coexist — and a patient who has read about one is often entirely unaware of the other.
Our job isn’t to talk anyone out of a supplement. It’s to make sure the full pharmacologic picture is on the table.
Why patients don’t tell you
As I wrote recently about kratom, the recurring theme in herbal supplements is that labels shape perception more than pharmacology does. Patients see “natural,” “plant-based,” and “supplement,” and reasonably conclude the product is harmless. Berberine is a textbook case: a pharmacologically active compound capable of altering how the body processes prescription medications, sold in the same aisle as multivitamins.
Product variability compounds it. Supplements often aren’t standardized, and commercial preparations differ meaningfully in content — so two patients who both report taking berberine may be taking very different doses. Add the common gastrointestinal effects reported across trials — nausea, abdominal pain, bloating, constipation, diarrhea — and “harmless” gets considerably harder to swallow. Pardon the pun.
None of this makes berberine dangerous. It doesn’t mean every patient taking it is at risk. It means berberine deserves the same scrutiny we extend to anything capable of altering human physiology.
The three questions
I’ve said this many times, and it applies to every supplement that will trend after this one:
What do you take? Why do you take it? Did you take it today?
Notice that none of those questions uses the word “medication.” A patient taking a daily berberine capsule for their metabolism may never think to mention it if you ask only about drugs and prescriptions. Broadening the question to include supplements, powders, and wellness products is what surfaces the information that matters most.
The three most important questions of any dental appointment:
What do you take? Why do you take it? Did you take it today?
Tom Viola, R.Ph., is a licensed pharmacist, clinical educator, and founder of Pharmacology Declassified. He has delivered over 2000 seminars and webinars to dental professionals since 2001.
References
Neag MA, Mocan A, Echeverría J, et al. Berberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. Front Pharmacol. 2018;9:557.
Och A, Och M, Nowak R, Podgórska D, Podgórski R. Berberine, a herbal metabolite in the metabolic syndrome. Molecules. 2022;27(4):1351.
Berberine and weight loss: what you need to know. National Center for Complementary and Integrative Health. Updated November 2023.
Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217.
Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients. Eur J Clin Pharmacol. 2005;61(8):567-572.
Lee DG, Kim MJ, Park SN, et al. Antimicrobial activity of berberine against oral bacteria related to endodontic infections. Int J Oral Biol. 2013;38(4):141-147.
